Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EOMCN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BL-M02D1
|
|||||
| Synonyms |
BL M02D1; BL-M02D1; BLM02D1
Click to Show/Hide
|
|||||
| Organization |
Sichuan Baili Pharmaceutical Co., Ltd.; Systimmune, Inc.; Chengdu Bailidote Biological Pharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Indication |
In total 3 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
hu4D3
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TROP2)
|
Antigen Info | ||||
| Payload Name |
Camptothecin analogue ED04
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05385692 | Clinical Status | Phase 1 | ||
| Clinical Description | Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic gastrointestinal tumors or other solid tumors. | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05339685 | Clinical Status | Phase 1 | ||
| Clinical Description | Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors. | ||||
References